Clarity Pharmaceuticals (ASX:CU6) Launches New Cancer Radiopharmaceutical

Highlights   

• Clarity Pharmaceuticals (CU6) advances a new radiopharmaceutical, SAR-bisFAP  
• The product targets multiple cancers with diagnostic and treatment potential  
• SAR-bisFAP demonstrated improved retention and uptake in preclinical trials   

Clarity Pharmaceuticals (ASX:CU6) has made significant progress in its cancer treatment pipeline with the development of a novel radiopharmaceutical known as SAR-bisFAP. Designed to offer both diagnostic and therapeutic capabilities, this new product showcases potential in addressing a wide spectrum of cancers.   

Radiopharmaceuticals combine radioactive isotopes with targeting molecules to seek out specific areas within the body, such as cancerous cells or tumors. The targeting molecule guides the isotope to its intended location, enabling accurate diagnosis through imaging tools like PET scans or direct treatment to eliminate cancer cells. Over time, the isotope decays and is naturally cleared from the body.   

The “SAR” in SAR-bisFAP reflects Clarity’s Specific Activity Radiopharmaceutical platform. This platform facilitates the attachment of copper isotopes, including copper-64 for imaging and copper-67 for therapeutic applications, to targeting molecules. The “FAP” refers to the Fibroblast Activation Protein, a protein found on fibroblasts associated with cancer tissue but largely absent in healthy tissue.   

FAP is prevalent in a range of cancers, including breast, lung, colorectal, pancreatic, brain, and ovarian cancers. The “bis” aspect of SAR-bisFAP indicates that the molecule features two binding sites. This dual-binding mechanism allows the product to attach to two FAP molecules simultaneously, enhancing its retention and stability at the target site.   

In preclinical studies, SAR-bisFAP demonstrated eight times higher retention and four times greater uptake compared to standard industry compounds like FAPI-46. These results highlight its potential efficacy and durability in targeting cancerous tissues.   

The company is currently conducting further investigations to support a Phase I clinical trial, anticipated to commence by late 2025. This expansion builds on the success of Clarity Pharmaceuticals’ SAR-bisPSMA product, developed for prostate cancer.   

The development of SAR-bisFAP underlines Clarity Pharmaceuticals’ (CU6) innovative approach in advancing radiopharmaceuticals that can address both diagnostic and treatment needs. The product’s broad applicability to multiple cancer types positions it as a significant addition to the company’s pipeline, marking progress in the evolving field of precision medicine.